About Advanced Life Sciences
Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events including statements regarding the Company's ability to comply with the minimum bid price requirements under the Nasdaq Marketplace Rules or any appeal associated therewith.
The Company does not undertake any obligations to update any
forward-looking statements whether as a result of new information, future
events or otherwise. Our actual results could differ materially from those
discussed herein due to several factors including the our ability to obtain
and maintain regulatory approval and labeling of our product candidates;
our plans to develop and commercialize our product candidates; the loss of
key scientific or management personnel; the size and growth of potential
markets for our product candidates and our ability to serve those markets;
regulatory developments in the U.S. and foreign countries; the rate and
degree of market acceptance of any future products; the accuracy of our
|SOURCE Advanced Life Sciences|
Copyright©2008 PR Newswire.
All rights reserved